Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...
Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax ... Pfizer's application was from an open-label study in Israel involving ...
Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...
Moderna is down 80% from its 52-week high as ... like potential approval of a next-gen COVID vaccine and a possible label expansion for the RSV vaccine due in 2025. An opportunity for an early ...
Branded as Spikevax, Moderna's (NASDAQ:MRNA) COVID-19 shot is indicated in the EU for active immunization of people aged six months and older. "Diversity of supply and availability of vaccine ...
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results